IL2 and cancer: Two phase I clinical trials (NCT00062855 and NCT01713439) studied the safety and dosage of an injection of neuroblastoma cancer cells that were genetically engineered to express XCL1 and IL-2, with the first using autologous cancer cells and the second using the allogenic SJNB-JF-IL2/Lptn cell line.